(3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-OL

Skin sensitisation

Administrative data

Endpoint:

skin sensitisation: in vivo (LLNA)

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2007-03-21 to 2007-06-18

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2007

Report date:

2007

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Type of study:

mouse local lymph node assay (LLNA)

Test material

Test material information

Constituent 1

Reference substance name:

(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol

EC Number:

605-076-4

Cas Number:

156928-09-5

Molecular formula:

C6H10O3

IUPAC Name:

(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol

Test material form:

liquid

Details on test material:

- Name of test material (as cited in study reports): T002675, TIC876
- Physical state: liquid
- Appearance: colorless to yellowish liquid

Specific details on test material used for the study:

SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: Tibotec Pharmaceuticals; 603T-1
- Expiration date of the lot/batch: December 19, 2007

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: At room temperature
- Stability under test conditions: N/A
- Solubility and stability of the test substance in the solvent/vehicle: N/A

TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The test item was placed into a volumetric flask glass beaker on a tared balance and the vehicle (DMF) was quantitatively added. The low dose of the test item concentration was prepared serially from the mid dose. For the high concentration the test item was used undiluted. Homogeneity of the test item in the vehicle was maintained during treatment
with the magnetic stirrer.

In vivo test system

Test animals

Species:

mouse

Strain:

other: CBA/CaOlaHsd

Sex:

female

Details on test animals and environmental conditions:

TEST ANIMALS
- Source: Harlan Netherlands
- Age at study initiation: 7-12 weeks at start of acclimatisation
- Weight at study initiation: 18.0-20.9 g (mean=19.0 g)
- Housing: Makrolon Type 1 cages with wire mesh top (EHRET GmbH, D-79302 Emmendingen) with granulated soft wood bedding (Harlan Winkelmann GmbH, D-33178 Borchen)
- Diet (e.g. ad libitum): pelleted standard diet, ad libitum (Harlan Winkelmann GmbH, D-33178 Borchen)
- Water (e.g. ad libitum): Rossdorf community tap water, ad libitum
- Acclimation period: Under test conditions after health examination. Only animals without any visible signs of illness were used. No time of acclimatization provided.


ENVIRONMENTAL CONDITIONS
- Temperature (deg C): 22 + /- 3
- Humidity (%): 30-70
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12/12


IN-LIFE DATES: From: 2007-03-29 To: 2007-04-04

Study design: in vivo (LLNA)

Vehicle:

dimethylformamide

Concentration:

25, 50, and 100%

No. of animals per dose:

4 animals per dose

Details on study design:

RANGE FINDING TESTS:
- Compound solubility: no data
- Irritation: A pre-test in 2 mice, test substance concentrations of 12.5, 25, 50, and 100% (w/v) were tested on one ear each. No irritation effects were observed at these concentrations after a single application.
- Lymph node proliferation response: no data

MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: LLNA
-Criteria used to consider a positive response: Exposure to at least one test concentration must result in incorporation of 3HTdR at least three times or greater than that recorded in the control mice, as indicated by the SI, and the data must be compatible with a conventional dose reponse, although allowances must be made (especially at higher concentrations) for either local toxicity or immunological suppression.

TREATMENT PREPARATION AND ADMINISTRATION:
- Each test group of mice was treated by topical application to the dorsal surface of each ear lobe wth the test substance at concentrations of 25%, 50%, and 100% in DMF. 25 uL was spread over the entire surface of each ear lobe once daily for three days. Another group of mice was treated with an equal volume of DMF alone.
- Five days after the first application, all mice were administered 250 uL of PBS containing 79.8 uCi/mL 3HTdR (equal to 19.95 uCi 3HTdR per mouse) by IV injection via a tail vein.
- Approximately five hours after treatment with 3HTdR, all mice were euthanized by intraperitoneal injection of Na-thiopental.
- The draining lymph nodes were rapidly excised and pooled for each group (8 nodes per group).
-Single cell suspensions (in phosphate buffered saline) of pooled lymph node cells were prepared by gentle mechanical disaggregation through stainless steel gauze (200 Rm mesh size). After washing two times with phosphate buffered saline (approx. 10 ml) the
lymph node cells were resuspended in 5 % trichloroacetic acid (approx. 3 ml) and incubated at approximately +4 °C for at least 18 hours for precipitation of macromolecules. The precipitates were then resuspended in 5 % trichloroacetic acid (1 ml) and transferred
to plastic scintillation vials with 10 ml of ‘Ultima Gold’ scintillation liquid and thoroughly mixed.
- The level of HTdR incorporation was measured on a B-scintillation counter. Background levels were also measured in two 1ml-aliquots of 5 % trichloroacetic acid.
- HTdR incorporation is expressed as the number of disintegrations per minute (DPM)

Positive control substance(s):

hexyl cinnamic aldehyde (CAS No 101-86-0)

Statistics:

The mean values and standard deviations were calculated in the body weight tables. A statistical analysis was conducted for assessment of the dose-response relationship. An EC3 value could not be calculated.

Results and discussion

Positive control results:

Stimulation index
5% (w/v) -2.04
10% (w/v) - 6.31
25% (w/v) - 12.45

Measurement DPM
5% (w/v) - 8152.94
10% (w/v) - 24974.40
25% (w/v) - 49155.3

EC3=6.1%. Considered to be a skin sensitizer.

In vivo (LLNA)

Results

Results 1

Parameter:

SI

Value:

2.26

Test group / Remarks:

4 animals in 25% w/v in DMF

Results 2

Parameter:

SI

Value:

0.8

Test group / Remarks:

4 animals in 50% w/v in DMF

Results 3

Parameter:

SI

Value:

1.49

Test group / Remarks:

4 animals in 100% w/v

Cellular proliferation data / Observations:

CELLULAR PROLIFERATION DATA
- DPM: 25% w/v = 9967.54
50% w/v = 3563.36
100% w/v = 6594.59
Control = 4437.49

DETAILS ON STIMULATION INDEX CALCULATION
-Since the lymph nodes of the animals of a dose group were pooled, DPM/node was determined by dividing the measured value by the number of lymph nodes pooled.

EC3 CALCULATION
- The EC3 Value could not be calculated, since all SI´s are below 3.

CLINICAL OBSERVATIONS:
-No mortality occurred during the study period.
- On day five, all animals showed reduction of spontaneous activity, eyelid closure, and ruffled fur.

BODY WEIGHTS
-The body weight of the animals, recorded prior to the first application was within the range commonly recorded for animals of this strain and age. The body weight of the animals, recorded on the day of preparation was reduced.

Applicant's summary and conclusion

Interpretation of results:

GHS criteria not met

Conclusions:

In this study Stimulation Indices of 2.26, 0.80, and 1.49 were determined with the test item at concentrations of 25, 50, and 100% in DMF. The EC3 value could not be calculated, since none of the tested concentrations induced an S.I. greater than 3.The test substance was not considered to be a skin sensitizer under the describer conditions.